OncoSec Medical Incorporated
ONCSQ · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | -0.00 | 0.00 |
| FCF Yield | -116,423.05% | -370.36% | -235.65% | -159.65% |
| EV / EBITDA | 0.03 | -0.14 | 0.40 | 1.13 |
| Quality | ||||
| ROIC | -257.47% | -79.70% | -47.03% | -25.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.96 | 0.76 | 0.84 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -8.17% | 11.42% | -29.50% | 46.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.03 | 0.07 | 0.77 | 1.49 |
| Interest Coverage | -228.41 | -659.41 | -1,695.31 | -3,534.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,179.84 | 0.00 | 0.00 | 0.00 |